Search Results - "Nurmohamed, M T"

Neutrophil activation identifies patients with active polyarticular gout by Vedder, D, Gerritsen, M, Duvvuri, B, van Vollenhoven, R. F, Nurmohamed, M. T, Lood, C

“…Abstract Background Gout is the most prevalent inflammatory arthritis in developed countries. A gout flare is mediated by phagocytosis of monosodium urate…”
Get full text

Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation by van Halm, V P, Peters, M J L, Voskuyl, A E, Boers, M, Lems, W F, Visser, M, Stehouwer, C D A, Spijkerman, A M W, Dekker, J M, Nijpels, G, Heine, R J, Bouter, L M, Smulders, Y M, Dijkmans, B A C, Nurmohamed, M T

“…Patients with rheumatoid arthritis (RA) have an increased cardiovascular risk, but the magnitude of this risk is not known precisely. A study was undertaken to…”
Get more information

Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system by van den Oever, I A M, Sattar, N, Nurmohamed, M T

“…Circumstantial evidence suggests that the innate immune system and coagulation system share a common evolutionary origin, which explains the extensive…”
Get more information

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients by Jamnitski, A, Krieckaert, C L, Nurmohamed, M T, Hart, M H, Dijkmans, B A, Aarden, L, Voskuyl, A E, Wolbink, G J

“…To investigate the relationship between serum etanercept levels and clinical response. In 292 etanercept-treated patients with rheumatoid arthritis clinical…”
Get more information

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study by Bartelds, G M, Wijbrandts, C A, Nurmohamed, M T, Stapel, S, Lems, W F, Aarden, L, Dijkmans, B A C, Tak, P P, Wolbink, G J

“…To investigate how antibodies against anti-tumour necrosis factor (anti-TNF) agents influence response after switching from infliximab to adalimumab in…”
Get more information

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis by Peters, M J L, Symmons, D P M, McCarey, D, Dijkmans, B A C, Nicola, P, Kvien, T K, McInnes, I B, Haentzschel, H, Gonzalez-Gay, M A, Provan, S, Semb, A, Sidiropoulos, P, Kitas, G, Smulders, Y M, Soubrier, M, Szekanecz, Z, Sattar, N, Nurmohamed, M T

“…To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS)…”
Get more information

The RAPID3 questionnaire as a screening tool to reduce the number of outpatient clinic visits: a retrospective cohort study by Wiegel, J., Seppen, B. F., ter Wee, M. M., Nurmohamed, M. T., Boers, M., Bos, W. H.

“…Background Treat-to-target strategies require frequent on-site evaluations of disease activity in patients with rheumatoid arthritis (RA), burdening patients…”
Get full text

The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study by Swart, I. A. P., Visman, I. M., Heslinga, M., van der Horst-Bruinsma, I. E., van Denderen, J. C., Nurmohamed, M. T.

“…Background Biologicals, such as anti-tumor necrosis factor (anti-TNF), reduce cardiovascular disease (CVD) in patients with inflammatory rheumatic diseases…”
Get full text

Patient perspective on exercise intervention in rheumatoid arthritis with high risk of cardiovascular disease: a pilot qualitative study by van den Hoek, J., Sobejana, M., van Nes, F., Metsios, G., Kitas, G., van der Leeden, M., Nurmohamed, M. T., van der Esch, M.

“…The objective of the study was to gain an insight into the perceptions and experiences of patients with rheumatoid arthritis and a high cardiovascular disease…”
Get full text

Exercise intervention on cardiorespiratory fitness in rheumatoid arthritis patients with high cardiovascular disease risk: a single-arm pilot study by Sobejana, M., van den Hoek, J., Metsios, G. S., Kitas, G. D., van der Leeden, M., Verberne, S., Jorstad, H. T., Pijnappels, M., Lems, W. F., Nurmohamed, M. T., van der Esch, M.

“…Objective In patients with rheumatoid arthritis (RA) with cardiovascular disease risk, it is unknown whether exercises are safe, improve cardiorespiratory…”
Get full text

Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis by Wiegel, J, Seppen, B F, Nurmohamed, M T, Bos, W H, Ter Wee, M M

“…The use of frequent electronic patient reported outcome measures (ePRO's) enables monitoring disease activity at a distance (telemonitoring) in patients with…”
Get full text

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up by Vogelzang, E H, Hebing, R C F, Nurmohamed, M T, van Kuijk, A W R, Kruijff, J W F, l'Ami, M J, Krieckaert, C L M, Wolbink, G

“…To determine the percentage non-adherence to etanercept in patients with rheumatoid arthritis during three years of follow-up. During study visits in this…”
Get full text

Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence by van Heuckelum, M, Linn, A J, Vandeberg, L, Hebing, R C F, van Dijk, L, Vervloet, M, Flendrie, M, Nurmohamed, M T, van Dulmen, S, van den Bemt, B J F, van den Ende, C H M

“…This study aims to explore the contribution of implicit attitudes and associations towards conventional disease-modifying antirheumatic drugs (cDMARDs),…”
Get full text

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis by Wolbink, G J, Voskuyl, A E, Lems, W F, de Groot, E, Nurmohamed, M T, Tak, P P, Dijkmans, B A C, Aarden, L

“…Objective: To investigate the relationship between serum trough infliximab levels and clinical response to infliximab treatment in patients with rheumatoid…”
Get full text

Clinical evaluation of optical spectral transmission imaging for detection of disease activity in rheumatoid arthritis by Blanken, AB, Korteweg, M, van Boheemen, L, van Vollenhoven, RF, Nurmohamed, MT, van der Laken, CJ

“…To investigate the performance and factors of influence of optical spectral transmission (OST) imaging as a new technique for measuring joint inflammation in…”
Get full text

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis by de Vries, M K, van der Horst-Bruinsma, I E, Nurmohamed, M T, Aarden, L A, Stapel, S O, Peters, M J L, van Denderen, J C, Dijkmans, B A C, Wolbink, G J

“…Immunogenicity, specifically the onset of antibodies against tumour necrosis factor (TNF) blocking agents, seems to play an important role in non-response to…”
Get more information

Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade by van Eijk, I C, Peters, M J L, Serné, E H, van der Horst-Bruinsma, I E, Dijkmans, B A C, Smulders, Y M, Nurmohamed, M T

“…Ankylosing spondylitis (AS) is associated with increased cardiovascular morbidity and mortality. Microvascular function has been linked to several risk factors…”
Get more information

Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis by van Halm, V P, Nielen, M M J, Nurmohamed, M T, van Schaardenburg, D, Reesink, H W, Voskuyl, A E, Twisk, J W R, van de Stadt, R J, de Koning, M H M T, Habibuw, M R, van der Horst–Bruinsma, I E, Dijkmans, B A C

“…Background: Rheumatoid arthritis is characterised by inflammation and an increased cardiovascular risk. It was recently shown that active early rheumatoid…”
Get full text

Elevated Fab glycosylation of anti-hinge antibodies by Koers, J, Derksen, NIL, Falkenburg, WJJ, Ooijevaar-de Heer, P, Nurmohamed, MT, Wolbink, GJ, Rispens, T

“…Rheumatoid arthritis (RA) is characterized by systemic inflammation and the presence of anti-citrullinated protein antibodies (ACPAs), which contain remarkably…”
Get full text

Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial by Ruwaard, J, L' Ami, MJ, Kneepkens, EL, Krieckaert, CLM, Nurmohamed, MT, Hooijberg, F, van Kuijk, AWR, van Denderen, JC, Burgemeister, L, Rispens, T, Boers, M, Wolbink, GJ

“…The majority of patients with a rheumatic disease treated with etanercept may be overexposed. Data regarding etanercept tapering are scarce, particularly in…”
Get full text